{"id":765800,"date":"2023-06-23T18:17:33","date_gmt":"2023-06-23T22:17:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/"},"modified":"2023-06-23T18:17:33","modified_gmt":"2023-06-23T22:17:33","slug":"xoma-added-to-the-russell-2000-and-russell-3000-indexes","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/","title":{"rendered":"XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">EMERYVILLE, Calif., June  23, 2023  (GLOBE NEWSWIRE) &#8212; XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been added to the Russell 2000<sup>\u00ae<\/sup> and Russell 3000<sup>\u00ae<\/sup> Indexes following its annual reconstitution, which took effect after the U.S. markets close on June 23, 2023.<\/p>\n<p align=\"left\">FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.\u00a0 Each year, the Russell indexes are reconstituted to capture the 4,000 largest US stocks, ranking them by total market capitalization.\u00a0 The Russell 2000<sup>\u00ae<\/sup> Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000<sup>\u00ae<\/sup> Index.\u00a0 Inclusion in the Russell 2000<sup>\u00ae<\/sup> Index results in automatic inclusion in the appropriate growth and value style indexes.\u00a0 Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.\u00a0 Approximately $12.1 trillion in assets are benchmarked against Russell\u2019s US indexes.<\/p>\n<p align=\"left\">\n        <strong>About XOMA Corporation<\/strong><br \/>\n        <br \/>XOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.\u00a0 XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.\u00a0 When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.\u00a0 The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).\u00a0 For more information about the Company and its portfolio, please visit www.xoma.com.<\/p>\n<p align=\"left\">\n        <strong>Forward-Looking Statements\/Explanatory Notes<\/strong><br \/>\n        <br \/>Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial and milestone payments to XOMA, the potential of XOMA\u2019s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time, XOMA\u2019s business forecast, the potential expansion and accelerated growth of XOMA\u2019s portfolio, and the potential for this portfolio to generate sustained cashflows and positive returns over time.\u00a0 In some cases, you can identify such forward-looking statements by terminology such as \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cseek,\u201d \u201cproject,\u201d \u201cexpect,\u201d \u201cmay,\u201d \u201cwill\u201d, \u201cwould,\u201d \u201ccould\u201d or \u201cshould,\u201d the negative of these terms or similar expressions.\u00a0 These forward-looking statements are not a guarantee of\u00a0XOMA\u2019s\u00a0performance, and you should not place undue reliance on such statements.\u00a0 These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic.\u00a0 Other potential risks to XOMA meeting these expectations are described in more detail in XOMA&#8217;s most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission.\u00a0 Consider such risks carefully when considering XOMA&#8217;s prospects. Any forward-looking statement in this press release represents XOMA&#8217;s beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date.\u00a0 XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law.<\/p>\n<p align=\"left\">EXPLANATORY NOTE: Any references to \u201cportfolio\u201d in this press release refer strictly to milestone and\/or royalty rights associated with a basket of drug products in development.\u00a0 Any references to \u201cassets\u201d in this press release refer strictly to milestone and\/or royalty rights associated with individual drug products in development.<\/p>\n<p align=\"left\">As of the date of this press release, all assets in XOMA\u2019s milestone and royalty portfolio, except Vabysmo<sup>\u00ae<\/sup> (faricimab) and IXINITY<sup>\u00ae<\/sup> [coagulation factor IX (recombinant)], are investigational compounds.\u00a0 Efficacy and safety have not been established.\u00a0 There is no guarantee that any of the investigational compounds will become commercially available.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;text-align: justify;vertical-align: middle;padding-left: 0;padding-right: 0;vertical-align: middle\">\n            <strong>XOMA Investor Contact\u00a0<\/strong>\n          <\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;text-align: justify;vertical-align: middle;padding-left: 0;padding-right: 0;vertical-align: middle\">\n            <strong>XOMA Media Contact<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;padding-left: 0;padding-right: 0;vertical-align: middle\">Juliane Snowden<\/td>\n<td style=\"text-align: justify;vertical-align: middle;padding-left: 0;padding-right: 0;vertical-align: middle\">Kathy Vincent<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;padding-left: 0;padding-right: 0;vertical-align: middle\">XOMA Corporation<\/td>\n<td style=\"text-align: justify;vertical-align: middle;padding-left: 0;padding-right: 0;vertical-align: middle\">KV Consulting &amp; Management<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;padding-left: 0;padding-right: 0;vertical-align: middle\">+1 646-438-9754<\/td>\n<td style=\"text-align: justify;vertical-align: middle;padding-left: 0;padding-right: 0;vertical-align: middle\">+1 310-403-8951<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: justify;vertical-align: middle;padding-left: 0;padding-right: 0;vertical-align: middle\">juliane.snowden@xoma.com<\/td>\n<td style=\"text-align: justify;vertical-align: middle;padding-left: 0;padding-right: 0;vertical-align: middle\">kathy@kathyvincent.com<\/td>\n<\/tr>\n<\/table>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzgyMSM1NjYyOTEyIzIwMjcwMTY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTA0OGMxNGEtMmJhNi00NzBjLTg1ZjQtZDJlNGU1YjRhZjg1LTEwMzg3NTM=\/tiny\/XOMA-Corporation.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) &#8212; XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes following its annual reconstitution, which took effect after the U.S. markets close on June 23, 2023. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.\u00a0 Each year, the Russell indexes are reconstituted to capture the 4,000 largest US stocks, ranking them by total market capitalization.\u00a0 The Russell 2000\u00ae Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000\u00ae Index.\u00a0 Inclusion in the Russell 2000\u00ae Index results in automatic inclusion in the appropriate growth &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765800","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) &#8212; XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes following its annual reconstitution, which took effect after the U.S. markets close on June 23, 2023. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.\u00a0 Each year, the Russell indexes are reconstituted to capture the 4,000 largest US stocks, ranking them by total market capitalization.\u00a0 The Russell 2000\u00ae Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000\u00ae Index.\u00a0 Inclusion in the Russell 2000\u00ae Index results in automatic inclusion in the appropriate growth &hellip; Continue reading &quot;XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-23T22:17:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzgyMSM1NjYyOTEyIzIwMjcwMTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes\",\"datePublished\":\"2023-06-23T22:17:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\\\/\"},\"wordCount\":774,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzgyMSM1NjYyOTEyIzIwMjcwMTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\\\/\",\"name\":\"XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzgyMSM1NjYyOTEyIzIwMjcwMTY=\",\"datePublished\":\"2023-06-23T22:17:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzgyMSM1NjYyOTEyIzIwMjcwMTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzgyMSM1NjYyOTEyIzIwMjcwMTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/","og_locale":"en_US","og_type":"article","og_title":"XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","og_description":"EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) &#8212; XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes following its annual reconstitution, which took effect after the U.S. markets close on June 23, 2023. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.\u00a0 Each year, the Russell indexes are reconstituted to capture the 4,000 largest US stocks, ranking them by total market capitalization.\u00a0 The Russell 2000\u00ae Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000\u00ae Index.\u00a0 Inclusion in the Russell 2000\u00ae Index results in automatic inclusion in the appropriate growth &hellip; Continue reading \"XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-23T22:17:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzgyMSM1NjYyOTEyIzIwMjcwMTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes","datePublished":"2023-06-23T22:17:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/"},"wordCount":774,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzgyMSM1NjYyOTEyIzIwMjcwMTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/","name":"XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzgyMSM1NjYyOTEyIzIwMjcwMTY=","datePublished":"2023-06-23T22:17:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzgyMSM1NjYyOTEyIzIwMjcwMTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzgyMSM1NjYyOTEyIzIwMjcwMTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/xoma-added-to-the-russell-2000-and-russell-3000-indexes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"XOMA Added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765800"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765800\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}